共 50 条
- [1] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumorsCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 259 - 269Cao, JunningZhang, JianPeng, WeiChen, ZhiyuFan, SonghuaSu, WeiguoLi, KeLi, Jin
- [2] Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Li, JinCao, JunningZhang, JianFan, SonghuaSai, YangMu, Hua
- [3] A phase I study of safety and pharmacokinetics of A166, a novel selective inhibitor of human epidermal growth factor receptor-2 in Chinese patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Liu, YonghengLian, WeiZhao, XiQi, WeiXu, JianXiao, LiangQing, YanXue, TongtongWang, Jingyi
- [4] Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trialInvestigational New Drugs, 2023, 41 : 808 - 815Ting DengLe ZhangYehui ShiGuiying BaiYueyin PanAizong ShenXinghua HanZhaoyi YangMingxia ChenHui ZhouYang LuoShirui ZhengYi Ba
- [5] Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2010, 16 (07) : 2187 - 2197Langenberg, Marlies H. G.Witteveen, Petronella O.Roodhart, Jeanine M.Verheul, Henk M. W.Mergui-Roelvink, Marjavan der Sar, JanaBrendel, ErichLaferriere, NicoleSchellens, Jan H. M.Voest, Emile E.
- [6] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Xu, J.Wang, Y.Ye, C. Y.Huang, C.Zhang, X. H.Sai, Y.Shen, L.Mu, H.
- [7] Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer, 10Jin LiXinmin ZhaoLei ChenHaiyi GuoFangfang LvKa JiaKe YvFengqing WangChuan LiJun QianChunlei ZhengYunxia Zuo
- [8] Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC CANCER, 2010, 10 : 529Li, JinZhao, XinminChen, LeiGuo, HaiyiLv, FangfangJia, KaYv, KeWang, FengqingLi, ChuanQian, JunZheng, ChunleiZuo, Yunxia
- [9] Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trialINVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 808 - 815Deng, TingZhang, LeShi, YehuiBai, GuiyingPan, YueyinShen, AizongHan, XinghuaYang, ZhaoyiChen, MingxiaZhou, HuiLuo, YangZheng, ShiruiBa, Yi
- [10] Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I TrialONCOLOGIST, 2023, : e1259 - e1267Cao, JunningGuo, HongqianJi, DongmeiShen, WeinaZhang, ShunHsieh, Chih-YiCai, Sui XiongTian, Ye EdwardXu, CongZhang, PinXu, Binghe